VAX

Veradigm and American College of Cardiology Launch Influenza Vaccination Education Initiative to Improve Cardiovascular Health

Retrieved on: 
Tuesday, February 13, 2024
Health Technology, White House, Federal Government, Data Management, Other Education, Technology, Practice Management, Pharmaceutical, Education, Professional Services, Infectious Diseases, Public Policy, Government, Cardiology, Biotechnology, Software, Data Analytics, Health, Senior, MD, Physician, American College of Cardiology, Cardiovascular disease, ACS, Practice management, EHR, Stroke, MBA, SCM, MDRX, Risk, HHS, Heart failure, Vaccination, Unitary state, CMSS, American College, Council, Acute coronary syndrome, Patient, Practice Fusion, CDC, ACC, Inc., VAX, Medical specialty, Evidence-based practice, Workflow, Pharmaceutical industry

Veradigm Inc. (NASDAQ: MDRX), a leading provider of healthcare data and technology solutions announced today the launch of TRANSFORM VAX, an American College of Cardiology (ACC)-sponsored initiative aimed at improving cardiovascular health through increased influenza vaccination education.

Key Points: 
  • Veradigm Inc. (NASDAQ: MDRX), a leading provider of healthcare data and technology solutions announced today the launch of TRANSFORM VAX, an American College of Cardiology (ACC)-sponsored initiative aimed at improving cardiovascular health through increased influenza vaccination education.
  • Influenza vaccination is associated with a lower risk for adverse cardiovascular events, with an overall 34% lower risk of major adverse cardiovascular events and a 45% lower risk among individuals with recent acute coronary syndrome (ACS).1 As part of this quality improvement initiative, Veradigm is delivering ACC-sponsored vaccination education messaging to a subset of cardiology practices using the Practice Fusion EHR (a Veradigm Network solution).
  • The messages appear as banner advertisements in an in-frame window adjacent to the EHR workflow that is separate and distinguishable from the clinical and practice management workflow within the EHR.
  • “Veradigm is proud to be working with the ACC to apply our real-world data in combination with our messaging capabilities to improve rates of recommended vaccinations for adults with cardiovascular disease,” said Stuart Green, Senior Vice President and General Manager at Veradigm.

Vicon Boosts its Unified VMS Platform by Integrating with Omnilert's AI Visual Gun Detection System

Retrieved on: 
Tuesday, December 19, 2023
VMS, Software, FBI, VAX, Telescopic sight

HAUPPAUGE, N.Y. and LEESBURG, Va., Dec. 19, 2023 /PRNewswire/ --Vicon Industries, Inc., a subsidiary of Cemtrex Inc. (Nasdaq: CETX, CETXP, CETXW), designer and manufacturer of video surveillance and access control software, hardware, and components, and Omnilert, a leader in active shooter solutions, announced today the integration of Valerus® VMS with Omnilert's AI visual gun detection system. With this powerful integration, Valerus users can now connect Omnilert Gun Detect to instantly trigger an alarm in Valerus when a firearm is detected by the AI in live video feeds, which then sets off a series of pre-planned responses once the threat is verified.

Key Points: 
  • Omnilert Gun Detect AI software leverages Vicon cameras to create an early gun detection solution.
  • In fractions of a second, the software can identify a gun threat and send an alert to Valerus operators.
  • "Vicon is committed to choosing leading-edge technology partners to integrate with our Valerus VMS solution," said Ashwin Chandranathan, Product Manager, VMS Software.
  • To learn more about Vicon or the various technologies, contact the company by filling out the form here , or emailing [email protected]

Actress Marcia Cross of HPV Cancers Alliance Speaks at Global HPV Event

Retrieved on: 
Tuesday, June 27, 2023
Center for Global Dialogue and Cooperation, VAX, Vaccination, Cancer, Cervical cancer, Woman, Movement, Cross, Organization, FAAFP, Patient, HPV, Knowledge, Health, Collaboration, Noise, World Health Organization, Birth control, Vaccine, MD

NEW YORK, June 27, 2023 /PRNewswire/ -- Emmy-nominated actress Marcia Cross will speak at Women Deliver 2023's Global Dialogue Series on Thursday, June 29th.

Key Points: 
  • NEW YORK, June 27, 2023 /PRNewswire/ -- Emmy-nominated actress Marcia Cross will speak at Women Deliver 2023's Global Dialogue Series on Thursday, June 29th.
  • Women Deliver 2023 is one of the largest multi-sectoral convenings to advance global gender equality, with an estimated 6,000 people attending the Kigali, Rwanda conference taking place July 17-20, 2023.
  • Leading up to the main event, another 200,000 people are expected to engage online through the Global Dialogue virtual events to network on key issues leading up to the conference.
  • Cross is the President and Co-Founder of HPV Cancers Alliance , an organization she started after she revealed her own battle with HPV-associated anal cancer.

Durlston Partners Appoints Meraj Bahram as Managing Partner

Retrieved on: 
Monday, February 13, 2023
Professional Services, Business, Technology, Other Technology, Human Resources, Finance, Consulting, Growth, Data science, Partner, Partner (business rank), VAX, Meraj Airlines, City, Video game, Durlston

Durlston Partners, an expert talent advisory firm specialising in technology, quantitative finance and data science, is delighted to announce that it has appointed Meraj Bahram as the firm’s new Managing Partner, effective from February 27th, 2023.

Key Points: 
  • Durlston Partners, an expert talent advisory firm specialising in technology, quantitative finance and data science, is delighted to announce that it has appointed Meraj Bahram as the firm’s new Managing Partner, effective from February 27th, 2023.
  • Meraj is an experienced executive who joined Durlston as a Partner in 2018 and has played an integral role in driving the firm’s growth.
  • As Managing Partner at Durlston, Meraj will be responsible for driving the business and accelerating the firm’s global expansion which commenced earlier this year with the opening of Durlston’s first international office in New York City.
  • Meraj Bahram, incoming Managing Partner at Durlston Partners, said: “I am thrilled to be taking on the role of Managing Partner at such an exciting time for Durlston.

PYRE Collaborates With Movie FEAR OF THE VAX NOTS to Incorporate Revolutionary Token

Retrieved on: 
Thursday, January 5, 2023
Fear, The Jamie Foxx Show, Love That Girl, FEAR, Jibber Jabber (TV series), VAX, The Goldmind Inc., Love, Bentley, Cryptocurrency, Music, Metaverse

Will the fear of fear become more deadly than the unvaccinated?

Key Points: 
  • Will the fear of fear become more deadly than the unvaccinated?
  • With a soon to be announced ensemble cast, FEAR OF THE VAX NOTS is set to be a belly gripping tongue-and-cheek comedy spoof.
  • That is the question," exclaims Valentino Jefferson, the screenwriter and Producer of FEAR OF THE VAX NOTS.
  • PYRE, a 3D avatar Metaverse company, in conjunction with Metaverse Solutions, is doing a first of its kind, token drop on Thursday, January 12, 2023.

Vicon Announces Valerus 22.2, Further Boosting its Unified VMS Platform

Retrieved on: 
Thursday, December 22, 2022
Cloud, SOC, Information security operations center, Access control, LPR, Security operations center, VAX, Noise, Map, VMS, Kverneland Group, Video game console, Valerus

HAUPPAUGE, N.Y., Dec. 22, 2022 /PRNewswire-PRWeb/ -- Vicon Industries, Inc., a subsidiary of Cemtrex Inc. (Nasdaq: CETX, CETXP), designer and manufacturer of video surveillance and access control software, hardware, and components, announced today the latest release of its Valerus VMS. These latest Valerus updates further enhance Vicon's holistic, unified platform strategy, and give users more control over video searches, storage, and display.

Key Points: 
  • Valerus 22.2 further enhances Vicon's unified platform for controlling video, access control, LPR, and other integrated applications.
  • These latest Valerus updates further enhance Vicon's holistic, unified platform strategy, and give users more control over video searches, storage, and display.
  • VMDC—which has traditionally been a popular feature with Vicon's legacy ViconNet VMS users—is now available in Valerus.
  • These latest Valerus updates further enhance Vicon's unified platform for controlling video, access control, LPR, and other integrated applications.

Vaxcyte Reports Third Quarter 2022 Financial Results and Provides Business Update

Retrieved on: 
Monday, November 7, 2022
Investment, Fast track (FDA), Ageing, Immunoglobulin G, Growth, SEC, Company, Periodontal disease, Private Securities Litigation Reform Act, Expected, Program, Infection, Regulation of tobacco by the U.S. Food and Drug Administration, Peterborough, U.S. Securities and Exchange Commission, General Administration of Sport of China, Antigen, SAN, Sutro Biopharma, G&A, Immunization, Disease, Meningitis, Exercise, GLOBE, IND, IPD, FDA, Vaccine, Chemistry, Fast Track, Population, Administration, PCV, Genetically modified bacteria, Vaccination, Tolerability, R, Safety, Adult, OPA, Food, Review, Key, Research and development, VAX, Success, Infant, Security (finance), Pharmaceutical industry, Clothing, Generic drug, COVID-19

SAN CARLOS, Calif., Nov. 07, 2022 (GLOBE NEWSWIRE) -- Vaxcyte, Inc. (Nasdaq: PCVX), a clinical-stage vaccine innovation company engineering high-fidelity vaccines to protect humankind from the consequences of bacterial diseases, today announced financial results for the third quarter ended September 30, 2022 and provided a business update.

Key Points: 
  • We believe these results support a best-in-class potential for VAX-24 and present an opportunity to set a new bar for immunogenicity standards for pneumococcal vaccines.
  • The aggregate net proceeds to Vaxcyte from this offering were approximately$650.7 million after deducting underwriting discounts and commissions and other offering expenses payable by Vaxcyte.
  • VAX-PG: Vaxcyte expects to nominate a final vaccine candidate for VAX-PG, its novel therapeutic vaccine designed to treat periodontal disease, by the end of 2022.
  • Vaxcyte undertakes no duty or obligation to update any forward-looking statements contained in this release as a result of new information, future events or changes in its expectations.

Vaxcyte Reports Positive Topline Data from Phase 1/2 Proof-of-Concept Study of its 24-Valent Pneumococcal Conjugate Vaccine Candidate Being Investigated for the Prevention of Invasive Pneumococcal Disease in Adults Aged 18-64

Retrieved on: 
Monday, October 24, 2022
SAN, Streptococcus pneumoniae, Conference, IND, Infection, Infant, Private Securities Litigation Reform Act, Investigational New Drug, Program, Mortality, Meningitis, 20B, Sinusitis, Chemistry, Bacteria, Subclinical infection, Streptococcus, Antigen, Immunoglobulin G, Pneumonia, Immunization, Company, 23F, GLOBE, Genetically modified bacteria, FDA, Sutro Biopharma, PD, Review, Vaccine, OPA, Security (finance), Ageing, U.S. Securities and Exchange Commission, Vaccination, PCV, Host, Immunodeficiency, Otitis media, Disease, Peterborough, SEC, Webcast, Periodontal disease, IPD, VAX, Adult, Safety, Fast Track, 10A, Death, Public health, Pharmaceutical industry, Generic drug, COVID-19

-- Vaxcyte to Advance Potential Best-in-Class VAX-24 Clinical Program in Adult and Pediatric Populations --

Key Points: 
  • These four incremental serotypes cover 10-15 percent of strains causing invasive pneumococcal disease (IPD) over the current standard-of-care in adults.
  • We are thrilled with these positive topline results from our Phase 1/2 proof-of-concept study, which met all of our objectives.
  • The study results demonstrate that VAX-24 has the potential to provide broader coverage and better immune responses relative to the standard-of-care.
  • Topline safety, tolerability and immunogenicity data from the infant Phase 2 study primary 3-dose immunization series are expected by 2025.

SK bioscience Appoints New Executives towards Global Business Growth

Retrieved on: 
Friday, October 21, 2022
Biochemistry, Bill, Doctor of Philosophy, Sanofi Pasteur, Therapy, Growth, CEPI, Akwa Ibom State Association of Nigeria, USA Inc., BMGF, Regulation of tobacco by the U.S. Food and Drug Administration, Electrical engineering, Biotechnology, HQ, BMS, OGD, Investment, VAX, Bristol Myers Squibb, University, Infection, Food, Epidemic, Coalition for Epidemic Preparedness Innovations, Company, Bill & Melinda Gates Foundation, Health, Industry, CDMO, SK Group, Plasma protein binding, CEO, Research, Virginia Tech, State university system, Head, Global Health, Coalition, Electricity, FDA, COVID-19, Pharmaceutical industry, Fine chemical, Pfizer, Microbiology

SK bioscience is accelerating its entry into the U.S. with the appointment of Dr. Harry Kleanthous.

Key Points: 
  • SK bioscience is accelerating its entry into the U.S. with the appointment of Dr. Harry Kleanthous.
  • The Company earlier appointed Dr. Hun Kim, Chief Technical Officer at SK bioscience, as Chief Executive Officer of SK bioscience USA, Inc., a new entity that will be established early next year.
  • The headquarters of SK bioscience USA, Inc. will be located in Boston, a vibrant center of biotechnology, large biopharma, and academia ecosystem.
  • SK bioscience is a global innovative vaccine and biotech company, committed to global pandemic preparedness in vaccine development and manufacturing for more equitable access.

The Vitamin Shoppe Launches "Snax for Vax" Campaign with Free Giveaway of Healthy Snacks to Anyone Receiving a Flu Vaccine this Season

Retrieved on: 
Wednesday, October 12, 2022
White House, The Vitamin Shoppe, NASDAQ, White, COVID-19, Multimedia, VAX, Partnership, Company, Mineral, Snack, CEO, Social media, FRG, Vitamin, View, Dietary supplement

SECAUCUS, N.J., Oct. 12, 2022 /PRNewswire/ -- The Vitamin Shoppe®, an omnichannel specialty retailer of nutritional products, today announced that it is offering a free protein bar or healthy snack to anyone with a documented flu vaccine shot, in a national "Snax for Vax" campaign to support healthy communities during flu season.

Key Points: 
  • The Vitamin Shoppe previously conducted a similar Snax for Vax giveaway in an effort to incentivize Covid-19 vaccines, in a 2021 partnership with the White House.
  • In the U.S., the Company conducts business through over 700 company-operated retail stores under The Vitamin Shoppe and Super Supplements banners, and via its website, www.vitaminshoppe.com .
  • The company is expanding its retail footprint via an innovative, omnichannel franchising model and opened its first franchise store in 2022.
  • Globally, The Vitamin Shoppe serves customers in select Asia, South America, and Central America markets through local omnichannel partners.